All News

Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 2022 ACR/EULAR EGPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical: obstructive airway, polyps, MM ⭐️Labs: eosinophilia & extravasc eos-inflamm bx, negative points for Hematuria, cANCA or PR3 - Least sensitive: 85%, but 99% specific @RheumNow https://t.co/6YWmabNzuH https://t.co/kLVqXzNTEf

Links:

Eric Dein ericdeinmd ( View Tweet)
If #dermatomyositis, it is TIFgamma1 that has the high risk of #cancer. If you can order this #AB and it is negative in adults do we need to do cancer screen at baseline? and repeatedly? Need more data. Great observation though. #myositis hub #ACR21 abst#688 @RheumNow https://t.co/zeQl0DACbJ

Links:

Janet Pope Janetbirdope ( View Tweet)

#ACR21 #Abstr1908 Potential prognostic biomarker for lymphoma in #sjogren. ISG15 (IFN-I) expression was consistently ⬆️in pts with lymphoma vs none, both in blood and salivary gland biopsy. Work needed re: relation to other markers, ethnicity @RheumNow https://t.co/8VYYEXpXSw https://t.co/ZIkpx5kUfu

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst 1916 England & colleagues determined if anti-MAA Ab = predictor of incident RA-ILD - Anti-MAA Ab significantly associated w/ incident RA-ILD - Strongly associated w/ higher concentrations anti-MAA - Antibody associations = antigen/isotype dependent #ACR21 @RheumNow https://t.co/z1RspmxBvc https://t.co/hvUm4O6RmX

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid disease properly is the current best strategy for treating RA-ILD. Abstr#1918 #ACR21 @RheumNow #ACRBest https://t.co/FpUK6upyOi
Richard Conway RichardPAConway ( View Tweet)
@Will_I_Am_Osler @zach_wallace_md @RheumNow Very nice, amazingly similar! - also 3/4 with IgG4 >5xULN - similar list of other diseases wonderful to have correlation over multiple continents, the beauty of an international meeting like #ACR21! https://t.co/vabBKNbd7u
David Liew drdavidliew ( View Tweet)
Machine learning algorithm demonstrated high level of accuracy (88%) and precision (0.95) in diagnosing potential cases of axSpA ⭐️Is there a role for ML to facilitate faster rheum eval for suspicious axSpA cases? Abs#1922 #ACR21 @RheumNow https://t.co/tAPfROPICU https://t.co/HJD37B9jZw

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Is there a relationship between the weather and RA disease activity?⛈️ #ACR21 Abs#1912 🌡️Temperature & humidity significantly affect pain, TJC & SJC 🌦️PGA was mostly influenced by humidity Should we take the weather into account when assessing patients? @RheumNow https://t.co/e3PewZWkLR
Mrinalini Dey DrMiniDey ( View Tweet)
RA ILD survival. The ‘smoking’ gun! RA ILD in VA pts mostly menand smokers - data showed disease activity of #RheumatoidArthritis & ⬆️HAQ both reduced survival independently #ACRBest #ACR21 abst#1918 @RheumNow https://t.co/8GD7rHV07t
Janet Pope Janetbirdope ( View Tweet)
Preventive Window of Opportunity in RA? Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract #0455 presented at the #ACR21 annual meeting. https://t.co/bCN1k5hhUc https://t.co/gpEHk0XIRc

Links:

Dr. John Cush RheumNow ( View Tweet)
PsO vs PsA patient and disease characteristics COPPAR registry: PsO pts 🔼mean BSA Both 🔼 % of biologic therapy sPGA and PASI 🔼PsO 🔽QOL and physical health in PsA 🔼daily work impairment PsA Abst # 1779 #ACR21 @RheumNow

swethaann23 swethaann23 ( View Tweet)

🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNow https://t.co/xzOaFIu06e @RheumNow https://t.co/tmr4USETJ3

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria: 🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease @RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR21 #Abstr1909 📢We need to stress the importance of hydroxychloroquine adherence to our patients. Adherence (>90% of the time) reduced premature CVD mortality by 52% in #rheumatoidarthritis and #lupus. The study didn’t adjust for smoking @RheumNow https://t.co/D9pGqwWhje https://t.co/R6r3cSexUB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Looking forward to the #ACR21 roundup by Drs. Cush and Kavanaugh at 7pm EST tonight. Always entertaining and informative. A highlight of ACR for me. We met in person the last time in Atlanta #ACR19. It’s virtual & the link is at @RheumNow Hope to meet in person again #ACR22 🤞 https://t.co/pgAcBExL7G
Dr. Antoni Chan synovialjoints ( View Tweet)
Can we predict who will develop #RA-ILD? Perhaps anti-MAA is the answer! #ACR21 Abs#1916 👉🏼⬆️anti-MAA antibody assoc with incident ILD risk 👉🏼Associations are antigen & isotype dependent 👉🏼Antibody measurement may be useful to risk stratify for RA-ILD @RheumNow https://t.co/nC0OkuWtGU
Mrinalini Dey DrMiniDey ( View Tweet)
ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j
David Liew drdavidliew ( View Tweet)
ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis Great effort and useful result, esp for trials #ACR21 @petercgrayson https://t.co/IYFyh5oYBT
Mike Putman EBRheum ( View Tweet)
⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
×